Nifty
Sensex
:
:
10890.30
36321.29
3.50 (0.03%)
2.96 (0.01%)

Pharmaceuticals & Drugs

Rating :
75/99

BSE: 524804 | NSE: AUROPHARMA

788.30
1.75 (0.22%)
16-Jan-2019 | 3:58PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  784.85
  •  791.60
  •  779.00
  •  786.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1884849
  •  14858.26
  •  830.45
  •  527.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 46,113.86
  • 21.00
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,622.18
  • 0.32%
  • 3.55

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.87%
  • 3.24%
  • 9.07%
  • FII
  • DII
  • Others
  • 0.06%
  • 14.38%
  • 21.38%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.26
  • 15.24
  • 6.07

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.30
  • 12.07
  • 3.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 47.02
  • 15.59
  • 6.14

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.53
  • 18.91
  • 18.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.00
  • 5.29
  • 4.48

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.79
  • 13.19
  • 12.53

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
4,751.40
4,435.89
7.11%
4,250.27
3,678.75
15.54%
4,049.09
3,641.63
11.19%
4,336.11
3,906.18
11.01%
Expenses
3,765.13
3,319.01
13.44%
3,539.21
2,844.81
24.41%
3,260.98
2,920.39
11.66%
3,310.53
3,011.34
9.94%
EBITDA
986.27
1,116.88
-11.69%
711.06
833.94
-14.73%
788.11
721.24
9.27%
1,025.58
894.84
14.61%
EBIDTM
20.76%
25.18%
16.73%
22.67%
19.46%
19.81%
23.65%
22.91%
Other Income
26.26
10.27
155.70%
43.73
22.09
97.96%
43.83
40.78
7.48%
33.05
23.72
39.33%
Interest
35.39
17.27
104.92%
29.54
16.87
75.10%
24.72
14.28
73.11%
18.86
14.26
32.26%
Depreciation
163.68
132.08
23.92%
154.53
131.18
17.80%
156.63
100.05
56.55%
138.08
111.14
24.24%
PBT
786.62
977.80
-19.55%
570.72
707.98
-19.39%
650.59
647.69
0.45%
901.69
793.16
13.68%
Tax
175.42
197.96
-11.39%
115.54
190.99
-39.50%
122.39
117.15
4.47%
306.94
217.67
41.01%
PAT
611.20
779.84
-21.62%
455.18
516.99
-11.96%
528.20
530.54
-0.44%
594.75
575.49
3.35%
PATM
12.86%
17.58%
10.71%
14.05%
13.04%
14.57%
13.72%
14.73%
EPS
10.44
13.33
-21.68%
7.78
8.85
-12.09%
9.02
9.09
-0.77%
10.16
9.89
2.73%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
17,386.87
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
3,575.44
3,077.28
Net Sales Growth
11.01%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
22.54%
16.19%
 
Cost Of Goods Sold
7,437.11
6,162.23
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
1,574.54
1,533.07
Gross Profit
9,949.76
10,300.80
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
2,000.90
1,544.21
GP Margin
57.23%
62.57%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
55.96%
50.18%
Total Expenditure
13,875.85
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
2,752.25
2,809.89
Power & Fuel Cost
-
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
194.91
182.72
% Of Sales
-
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
5.45%
5.94%
Employee Cost
-
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
324.13
240.89
% Of Sales
-
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
9.07%
7.83%
Manufacturing Exp.
-
1,534.44
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
349.01
268.67
% Of Sales
-
9.32%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
9.76%
8.73%
General & Admin Exp.
-
1,068.21
997.32
686.38
666.38
283.49
197.83
130.74
120.34
116.94
104.63
% Of Sales
-
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
3.27%
3.40%
Selling & Distn. Exp.
-
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
143.56
152.87
% Of Sales
-
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
4.02%
4.97%
Miscellaneous Exp.
-
298.76
203.97
187.92
227.09
123.20
149.49
111.96
47.53
49.16
152.87
% Of Sales
-
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
1.37%
10.63%
EBITDA
3,511.02
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
823.19
267.39
EBITDA Margin
20.19%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
23.02%
8.69%
Other Income
146.87
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
151.49
26.05
Interest
108.51
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
73.09
93.22
Depreciation
612.92
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
149.34
127.60
PBT
2,909.62
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Tax
720.29
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
191.36
21.36
Tax Rate
24.76%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
25.44%
29.41%
PAT
2,189.33
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
561.21
51.31
PAT before Minority Interest
2,189.29
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
560.89
51.26
Minority Interest
-0.04
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
0.32
0.05
PAT Margin
12.59%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
15.70%
1.67%
PAT Growth
-8.89%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
0.40%
993.76%
 
Unadjusted EPS
37.40
41.36
39.33
34.67
27.03
40.27
10.09
-4.24
19.57
20.81
18.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
1,829.08
1,241.26
Share Capital
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
27.86
26.88
Total Reserves
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
1,801.22
1,214.38
Non-Current Liabilities
583.54
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
2,245.74
2,409.84
Secured Loans
26.96
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
864.05
987.67
Unsecured Loans
424.24
3.81
362.71
587.93
178.05
64.15
102.55
73.61
1,290.51
1,345.30
Long Term Provisions
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
0.00
0.00
Current Liabilities
8,680.62
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
707.99
570.05
Trade Payables
2,627.44
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
604.40
514.77
Other Current Liabilities
1,777.80
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
68.40
28.69
Short Term Borrowings
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
0.00
0.00
Short Term Provisions
244.04
261.36
132.93
218.24
126.60
80.09
66.36
58.32
35.19
26.59
Total Liabilities
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30
Net Block
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
1,710.85
1,398.77
Gross Block
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
2,407.67
1,973.63
Accumulated Depreciation
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
696.82
574.86
Non Current Assets
8,758.56
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
2,280.47
1,934.61
Capital Work in Progress
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
570.08
536.30
Non Current Investment
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
-0.46
-0.46
Long Term Loans & Adv.
255.76
256.48
236.56
455.27
789.04
237.82
108.12
110.77
0.00
0.00
Other Non Current Assets
87.56
81.29
32.24
30.25
18.40
18.66
0.12
1.47
0.00
0.00
Current Assets
12,187.84
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
2,506.67
2,289.69
Current Investments
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
0.74
0.72
Inventories
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
1,102.45
877.63
Sundry Debtors
3,084.36
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
956.01
889.76
Cash & Bank
1,261.62
513.48
800.26
469.11
178.58
208.45
70.86
186.72
72.83
127.65
Other Current Assets
1,983.43
1,084.72
464.37
271.67
448.46
407.69
388.98
448.17
374.64
393.93
Short Term Loans & Adv.
760.11
512.09
366.88
387.90
237.22
207.51
216.67
358.87
280.60
333.16
Net Current Assets
3,507.22
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
1,798.68
1,719.64
Total Assets
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,954.82
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
425.18
136.03
PBT
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Adjustment
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
99.77
427.84
Changes in Working Capital
-1,068.98
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
-273.72
-334.21
Cash after chg. in Working capital
2,707.22
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
578.30
166.25
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-752.40
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
-153.12
-30.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,956.95
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
-399.02
-406.28
Net Fixed Assets
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
-478.66
-288.52
Net Investments
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
-101.50
18.54
Others
-900.40
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
181.14
-136.30
Cash from Financing Activity
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
-84.04
164.99
Net Cash Inflow / Outflow
862.02
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
-57.88
-105.26
Opening Cash & Equivalents
319.63
743.49
403.81
148.02
202.73
65.64
183.71
44.72
102.65
235.68
Closing Cash & Equivalent
1,211.84
319.63
743.50
461.10
148.02
202.73
65.64
183.71
47.19
96.96

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
32.83
23.09
ROA
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
12.45%
1.30%
ROE
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
36.54%
4.33%
ROCE
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
21.84%
5.07%
Fixed Asset Turnover
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
1.72
Receivable days
64.70
89.16
106.53
91.84
93.55
86.28
95.44
89.07
92.25
89.57
Inventory Days
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
98.97
96.37
Payable days
71.58
75.73
81.50
67.49
71.06
57.79
64.70
70.79
72.18
71.28
Cash Conversion Cycle
105.81
114.86
125.30
113.25
117.31
134.00
146.65
122.45
119.04
114.66
Total Debt/Equity
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
1.88
Interest Cover
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19
11.29
1.78

News Update:


  • Aurobindo Pharma’s arm recalls 80 lots of blood pressure drug from America
    2nd Jan 2019, 10:13 AM

    This is done due to presence of impurity found in the finished drug product that may cause cancer in humans

    Read More
  • Aurobindo Pharma’s injectable business achieves $50 million revenue in Q2
    27th Dec 2018, 14:59 PM

    The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval

    Read More
  • Aurobindo Pharma receives USFDA nod for Vecuronium Bromide Injection
    24th Dec 2018, 10:16 AM

    Vecuronium Bromide Injection is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation

    Read More
  • Aurobindo Pharma receives USFDA’s nod for Potassium Chloride ER Tablets
    21st Dec 2018, 14:04 PM

    Potassium Chloride Extended-Release tablets, a generic version of Upsher-Smith’s Klor-Con Extended Release tablets

    Read More
  • Aurobindo Pharma’s arm enters into agreement with Luoxin
    11th Dec 2018, 15:38 PM

    The agreement aims to establish a JV company in China with manufacturing facilities to manufacture nebuliser inhaler

    Read More
  • Aurobindo Pharma expecting first biosimilar approval in US in 12-18 months
    3rd Dec 2018, 12:49 PM

    In Europe, the company hopes a green signal by 2022

    Read More
  • Aurobindo Pharma planning to launch oncology, respiratory products in US
    19th Nov 2018, 10:00 AM

    The company is also planning to launch first set of biosimilars and vaccines in growth markets

    Read More
  • Aurobindo Pharma reports 22% fall in Q2 consolidated net profit
    13th Nov 2018, 10:07 AM

    Total consolidated income of the company increased by 7.46% at Rs 4,777.66 crore for Q2FY19

    Read More
  • Aurobindo Pharma’s arm enters into agreement with Advent Pharma
    13th Nov 2018, 08:59 AM

    This acquisition will provide an opportunity to acquire assets that would be used for specialty generics business

    Read More
  • Aurobindo Pharma - Quarterly Results
    12th Nov 2018, 19:26 PM

    Read More
  • Aurobindo Pharma receives USFDA’s nod for Azithromycin Oral Suspension
    11th Oct 2018, 11:22 AM

    The product will be launched in November 2018

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.